We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00763607
First Posted: October 1, 2008
Last Update Posted: September 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Istituto Clinico Humanitas
  Purpose

Aim of the study is to evaluated the role of IGF1R and p95HER2 on prognosis in radically resected non small cell lung cancer patients

The primary objective is to correlate the expression of IGF1R and p95HER2 with survival.


Condition Intervention
Non Small Cell Lung Cancer Genetic: Protein expression by immunohistochemistry and immunofluorescence

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Radically Resected Non Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Istituto Clinico Humanitas:

Primary Outcome Measures:
  • Association of different biomarkers with survival [ Time Frame: At the end of enrollment ]

Secondary Outcome Measures:
  • Association of a specific biomarker with patient's characteristics [ Time Frame: At the end of enrollment ]

Biospecimen Retention:   Samples With DNA
Paraffine embedded tumor sections

Estimated Enrollment: 454
Study Start Date: November 2007
Study Completion Date: December 2009
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Radically resected Non small cell lung cancer patients in stage I-III
Genetic: Protein expression by immunohistochemistry and immunofluorescence
Protein expression by immunohistochemistry and immunofluorescence

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Radically resected non small cell lung cancer patients
Criteria

Inclusion Criteria:

  • Radically resected non small cell lung cancer patients with tumor tissue available

Exclusion Criteria:

  • Tumor tissue not available
  • Clinical data not available
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00763607


Locations
Italy
Istituto Clinco Humanitas
Rozzano, Milan, Italy, 20089
Sponsors and Collaborators
Istituto Clinico Humanitas
Investigators
Principal Investigator: Armando Santoro, MD Istituto Clinico Humanitas
  More Information

Responsible Party: Armando Santoro, MD, Istituto Clinico Humanitas
ClinicalTrials.gov Identifier: NCT00763607     History of Changes
Other Study ID Numbers: ONC/OSS-02/2007
First Submitted: September 30, 2008
First Posted: October 1, 2008
Last Update Posted: September 2, 2010
Last Verified: September 2010

Keywords provided by Istituto Clinico Humanitas:
non small cell lung cancer patients

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms